The WACC of Cuu Long Pharmaceutical JSC (DCL.VN) is 8.9%.
| Range | Selected | |
| Cost of equity | 8.60% - 12.30% | 10.45% |
| Tax rate | 20.30% - 20.40% | 20.35% |
| Cost of debt | 6.00% - 6.40% | 6.20% |
| WACC | 7.5% - 10.2% | 8.9% |
| Category | Low | High |
| Long-term bond rate | 2.7% | 3.2% |
| Equity market risk premium | 9.5% | 10.5% |
| Adjusted beta | 0.62 | 0.82 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 8.60% | 12.30% |
| Tax rate | 20.30% | 20.40% |
| Debt/Equity ratio | 0.41 | 0.41 |
| Cost of debt | 6.00% | 6.40% |
| After-tax WACC | 7.5% | 10.2% |
| Selected WACC | 8.9% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for DCL.VN:
cost_of_equity (10.45%) = risk_free_rate (2.95%) + equity_risk_premium (10.00%) * adjusted_beta (0.62) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.